NanoDx
I came across diagnostic startup Nano Diagnostics recently. The approach they originally proposed was nanowire based. Somewhat reminiscent of QuantumDx. QuantumDx originally proposed a nanowire based approach, but as far as I can tell have more recently dumped it in favor of fairly traditional qPCR-based approaches. As we will see in the patents, NanoDx may have also made a bit of a shift as well.
NanoDx was founded ~15 years ago in 2010 as Biodirection. With a thesis around the detection of traumatic brain injuries and point-of-care concussion diagnosis.
In the mean time, biomarkers for concussion appear to have become better established, with Abbott offering a more conservative immunoassays based detection platform (receiving clearance in 2023), which they say provides results in 15 minutes and has been moving into a point-of-care context1.
That likely makes the NanoDx concussion diagnostics play more challenging. This is perhaps why they talk more about SARS-CoV-2 in more recent patents.
Let’s take a look and see what they have!